The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12611000404921
Ethics application status
Approved
Date submitted
4/04/2011
Date registered
19/04/2011
Date last updated
19/04/2011
Type of registration
Prospectively registered

Titles & IDs
Public title
Efficacy and safety of chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in Ratchaburi, Trat and Chanthaburi provinces of Thailand
Scientific title
Efficacy and safety of chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in Ratchaburi, Trat and Chanthaburi provinces of Thailand
Secondary ID [1] 259906 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Uncomplicated vivax malaria patients 265510 0
Condition category
Condition code
Infection 265661 265661 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Oral chloroquine tablet (25 mg base/kg divided to be given over 3 days; day 0, 5 mg base/kg per/meal for 3 meals; day 1, 5 mg/kg; day 2, 5 mg/kg). In this trial, we study the efficacy of chloroquine alone for the treatment of uncomplicated vivax malaria. So we give Primaquine after study finished. The standard treatment of vivax malaria patient in Thailand is 25 mg base/kg divided to be given over 3 days plus primaquine 20 mg base taken daily for 14 days.
Intervention code [1] 264330 0
Treatment: Drugs
Comparator / control treatment
The study will be done in 3 sentinel sites for Chloroquine treatment of uncomplicatd vivax malaria patients.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 266444 0
Treatment outcomes will be classified on the basis of an assessment of the parasitological and clinical outcome of antimalarial treatment according to the latest World Health Organization (WHO) guidelines. Thus, all patients will be classified as having early treatment failure, late clinical failure, late parasitological failure or an adequate clinical and parasitological response.
Timepoint [1] 266444 0
Day 1, 2, 3, 7, 14, 21, and 28
Secondary outcome [1] 273791 0
The incidence of any adverse event such as nausea, vomiting, diarrhea, etc. will be documented. All patients will be asked routinely about the previous symptoms and about symptoms that have emerged since the previous follow-up visit. When clinically indicated, patients will be evaluated and treated appropriately. All adverse events will be recorded on the case report form. Serious adverse events must be reported to the sponsor.
Timepoint [1] 273791 0
Day 1, 2, 3, 7, 14, 21, and 28

Eligibility
Key inclusion criteria
-Age 6 months and above;
-Mono-infection with Plasmodium vivax for vivax malaria patients detected by microscopy
-P. vivax paraasitemia of >250/ul asexual forms
-presence of axillary or tympanic temperature equal or more than 37.5C or history of fever during the past 24 h
-Ability to swallow oral medication
-Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule and
-Informed consent from the patient or from a parent or guardian in the case of children
Minimum age
6 Months
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
-Presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO -mixed or mono-infection with another Plasmodium species detected by microscopy -presence of severe malnutrition (defined as a child whose growth standard is below -3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference <110 mm) -presence of febrile conditions due to diseases other than malaria or other known underlying chronic or severe diseases -Regular medication, which may interfere with antimalarial pharmacokinetics -history of hypersensitivity reactions or contraindications to any of the medicine being tested or used as alternative treatment -Female of child-bearing potential with ages 12-17 years old inclusive -A positive pregnancy test or breastfeeding -Unable to or unwilling to take contraceptives for pregnancy negative married women of child-bearing age

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment outside Australia
Country [1] 3332 0
Thailand
State/province [1] 3332 0
Chanthaburi
Country [2] 3333 0
Thailand
State/province [2] 3333 0
Trat
Country [3] 3334 0
Thailand
State/province [3] 3334 0
Ratchaburi

Funding & Sponsors
Funding source category [1] 264793 0
Other
Name [1] 264793 0
World Health Organization
Address [1] 264793 0
WHO-Mekong Malaria Programme (MMP) Faculty of Tropical Medicine, Mahidol University, 400/6 Ratchawithi Road, 10400 Bangkok, Thailand
Country [1] 264793 0
Thailand
Primary sponsor type
Government body
Name
Bureau of Vector-Borne Disease
Address
Department of Disease Control, Ministry of Public Health, Tiwanon Road, Muang District, Nonthaburi 11000
Country
Thailand
Secondary sponsor category [1] 263905 0
None
Name [1] 263905 0
Address [1] 263905 0
Country [1] 263905 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 266765 0
The Ethical Committee for Research in Human Subjects
Ethics committee address [1] 266765 0
Department of Disease Control, Ministry of Public Health, Tiwanon Road, Muang District, Nonthaburi 11000
Ethics committee country [1] 266765 0
Thailand
Date submitted for ethics approval [1] 266765 0
07/04/2010
Approval date [1] 266765 0
07/05/2010
Ethics approval number [1] 266765 0
3/52-293

Summary
Brief summary
Title: Efficacy and safety of chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in Ratchaburi, Trat and Chanthaburi provinces in Thailand
Background: Current first-line treatment for P. vivax in Thailand is chloroquine. Study conducted in 2009 in 2 sentinel sites revealed high efficacy of the chloroquine (100%). The monitoring the efficacy of the first line treatment to generate valuable information for updating the national treatment policy is critical.
Objective: To assess the efficacy and safety of chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in Ratchaburi, Trat and Chanthaburi provinces in Thailand
Methods: Antimalarial drug efficacy trials will be conducted in 3 sites. The participants will be febrile patients aged 6 months and above with confirmed uncomplicated P. vivax infection. Vivax malaria patients will be treated with Chloroquine 25 mg base/kg divided over 3 days; day 0, 5 mg base/kg per/meal for 3 meals; day 1, 5 mg/kg; day 2, 5 mg/kg. Clinical and parasitological parameters will be monitored over a 28-day follow-up period to evaluate drug efficacy for vivax malaria. The study will be conducted from May 2011 to May 2012. The results of this study will be used to assist the Ministry of Public Health of Thailand in assessing the current national treatment guidelines for uncomplicated P. vivax malaria.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 32431 0
Address 32431 0
Country 32431 0
Phone 32431 0
Fax 32431 0
Email 32431 0
Contact person for public queries
Name 15678 0
Dr. Kanungnit Congpuong
Address 15678 0
Bureau of Vector-Borne Disease,
Department of Disease Control,
Ministry of Public Health,
Tiwanon Road, Muang District,
Nonthaburi, 11000
Country 15678 0
Thailand
Phone 15678 0
662 965 9608
Fax 15678 0
662 591 8422
Email 15678 0
kanungnitcongpuong@ymail.com
Contact person for scientific queries
Name 6606 0
Dr. Kanungnit Congpuong
Address 6606 0
Bureau of Vector-Borne Disease,
Department of Disease Control,
Ministry of Public Health,
Tiwanon Road, Muang District,
Nonthaburi, 11000
Country 6606 0
Thailand
Phone 6606 0
662 965 9608
Fax 6606 0
662 591 8422
Email 6606 0
kanungnitcongpuong@ymail.com

No information has been provided regarding IPD availability
Summary results
No Results